Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. is an orphan‑focused, neuropsychiatric biopharmaceutical company based in Devon, Pennsylvania. It pioneers transdermal cannabinoid therapies for rare neurological disorders, notably developing Zygel (ZYN002), a permeation‑enhanced cannabidiol gel for conditions like Fragile X and 22q11.2 deletion syndrome.
Address: 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462
Phone: (484) 539-9800
-
Plymouth Meeting’s Harmony Biosciences Drug Trial Misses Mark, Shares Drop
Plymouth Meeting’s Harmony Biosciences saw its stock tumble more than 16% this week, writes John George for the Philadelphia Business…
-
Plymouth Meeting’s Harmony Biosciences Holdings Acquires Zynerba Pharmaceuticals
Harmony Biosciences Holdings in Plymouth Meeting has agreed to buy Zynerba Pharmaceuticals for up to $200 million, writes John George…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
